- cafead Jul 09, 2021 at 09:52: AM
via Biohaven showed yesterday that not all launches by small companies end in disaster. And impressive second-quarter sales of its oral migraine therapy, Nurtec ODT, will only have increased speculation that the group could be a takeover target.
One company that might do well to consider buying Biohaven is Glaxosmithkline, which needs some fresh blood to placate the activist investor Elliott Management.
article source
One company that might do well to consider buying Biohaven is Glaxosmithkline, which needs some fresh blood to placate the activist investor Elliott Management.
article source